drugset / Trial / NCT01242930
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label Phase II study to determine the rate of improvement in response of patients with previously treated multiple myeloma to imetelstat alone or in combination with lenalidomide maintenance therapy. This study will include multiple myeloma patients who either have achieved disease stabilization or who have achieved at least a partial response (PR) but failed to achieve a complete response (CR) after cytoreductive therapy for multiple myeloma; ie, have detectable but non-progressing disease and will most likely relapse.
Timeline
- Start
- 2010-11
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imetelstat | Oligonucleotide (other) | 7.5 mg/kg | Intravenous |
| Subject | Imetelstat | Oligonucleotide (other) | 9.4 mg/kg | Intravenous |
| Background | Lenalidomide | Other / unclassified | — | — |